The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVGR.L Regulatory News (AVGR)

  • There is currently no data for AVGR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Solicitation Agent

23 Sep 2015 07:00

RNS Number : 8829Z
AvangardCo Investments Public Ltd
23 September 2015
 

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED).

 

23 September 2015

 

Appointment of UBS Limited as Solicitation Agent for Avangardco Investments Public Limited's UK Scheme of Arrangement

 

Appointment of Solicitation Agent

 

UBS Limited has been appointed as sole solicitation agent in relation to the UK scheme of arrangement (the "Scheme") launched on 17 September 2015 by Avangardco Investments Public Limited (the "Company") to seek the sanction of the High Court of Justice in England and Wales to (i) waive certain events of default (the "Waiver") under, and (ii) amend and extend (the "Amendments") the Company's US$200 million 10.0% Notes due 2015 (ISIN: XS0553088708) (the "Notes").

 

Requests for all information in relation to the above, including requests by holders of Notes for copies of the documentation, should be directed to:

 

UBS Limited

1 Finsbury Avenue

London EC2M 2PP

United Kingdom

 

Tel: +1-203-719-8682 / +44 20756 84601

E-mail: mark-t.watkins@ubs.com / torstein.berteig@ubs.com

Attention: Liability Management Group

 

 

Cash flows of amended Notes

 

The terms and conditions of the Scheme, including the Waiver and the Amendments, were announced by the Company on 17 September 2015 (the "Announcement") and are included in a Practice Statement Letter dated 17 September 2015 prepared in connection with the Scheme. You may access the Announcement, the Practice Statement Letter and other information in relation to the Scheme made available from time to time on the following website upon providing appropriate certifications: http://sites.dfkingltd.com/avangard.

 

A table of cash flows on the Notes following the implementation of the Scheme and the incorporation of the Amendments is set forth below.

Interest payment date

Principal amount outstanding[1][2]

Cash Interest %

PIK Interest %

Cash coupon[3]

PIK coupon[4]

Principal redemption

29/10/15

US$103,000

 40

 60

US$2,000

US$3,000

-

29/04/16

US$106,863

 25

 75

US$1,288

US$3,863

-

29/10/16

US$110,870

 25

 75

US$1,336

US$4,007

-

29/04/17

US$113,642

 50

 50

US$2,772

US$2,772

-

29/10/17

US$116,483

 50

 50

US$2,841

US$2,841

-

29/04/18

US$117,939

 75

 25

US$4,368

US$1,456

-

29/10/18

US$117,939

 100

 0

US$5,897

-

US$117,939

 

--------

 

Certain information about the Company, the Scheme, the Waiver, the Amendments and the Group's current acute shortage of liquidity has been included in a Practice Statement Letter dated 17 September 2015 prepared in connection with the Scheme. You may access the Practice Statement Letter and other information in relation to the Scheme made available from time to time on the following website upon providing appropriate certifications: http://sites.dfkingltd.com/avangard. For further information please contact D.F. King Ltd.

  

D.F. King Ltd. as the Scheme Information AgentEmail: avangard@dfkingltd.com

Website: sites.dfkingltd.com/avangard

 

In London:85 Gresham StreetLondon, EC2V 7NQUnited KingdomTelephone: +44 20 7920 9700

 

In Hong Kong:Suite 1601, 16/F, Central Tower28 Queen's Road CentralHong KongTelephone: +852 3953 7230

 

In New York:

48 Wall Street, 22nd Floor

New York, New York 10005

United States

Telephone: +1 212 269 5550

 

--------

 

This notice is neither an offer to purchase nor a solicitation of an offer to sell securities. The Scheme is not being made to any person in any jurisdiction in which the making of the Scheme would not be in compliance with the securities or other laws of such jurisdiction. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States, unless registered under the Securities Act or unless an exemption from the registration requirements set forth in the Securities Act applies to them. No public offering of the securities will be made in the United States and the Company does not intend to make any such registration under the Securities Act.

 

In the United Kingdom, this communication is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (b) high net worth entities falling within Article 49(2)(a) to (d) of the Order and (c) other persons to whom it may be lawfully communicated (all such persons together being referred to as "relevant persons"). Any person who is not a relevant person should not act or rely on this communication or any of its contents.

 

Statements contained herein may constitute "forward-looking statements". Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "aim", "plan", "expect", "anticipate", "estimate", "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology.

 

Forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.

 

 

 

 

 


[1] Principal amount outstanding immediately following the relevant interest payment.

[2] Calculation based on a holding of US$100,000 of Notes.

[3] Cash interest rounded to the nearest US dollar.

[4] PIK interest rounded to the nearest US dollar.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZMGZLLZLGKZM
Date   Source Headline
23rd Aug 20167:00 amRNSNotice of Results
18th Aug 20163:46 pmRNSNotice of AGM
31st May 20167:00 amRNS1st Quarter Results
24th May 20169:55 amRNSNotice of Results
29th Apr 201610:16 amRNSBoard Changes And New CEO Appointment
22nd Apr 20162:00 pmRNS2015 Annual Report Publication
1st Apr 20163:46 pmRNSSecond Price Monitoring Extn
1st Apr 20163:40 pmRNSPrice Monitoring Extension
30th Mar 20167:00 amRNSRESULTS FOR Q4 AND THE YEAR ENDED 31 DECEMBER 2015
24th Mar 201610:41 amRNSNotice of Results
30th Nov 20153:40 pmRNSPrice Monitoring Extension
30th Nov 20157:00 amRNS3rd Quarter Results
28th Oct 201511:53 amRNSSCHEME CLOSING DATE NOTICE
23rd Oct 20153:29 pmRNSScheme Meeting Results
16th Oct 20153:04 pmRNSScheme of Arrangement -Early Participation Results
7th Oct 201510:09 amRNSAccession Mechanics Update and Reminder
28th Sep 201511:41 amRNSAccession Mechanics
24th Sep 20153:56 pmRNSNOTICE OF SCHEME MEETING
23rd Sep 20153:45 pmRNSSecond Price Monitoring Extn
23rd Sep 20153:40 pmRNSPrice Monitoring Extension
23rd Sep 20157:00 amRNSAppointment of Solicitation Agent
21st Sep 20153:40 pmRNSPrice Monitoring Extension
17th Sep 20156:06 pmRNSPRACTICE STATEMENT LETTER
17th Sep 20156:00 pmRNSAvangardco IPL UK Scheme of Arrangement
17th Sep 20151:02 pmRNSResults of AGM
8th Sep 20153:40 pmRNSPrice Monitoring Extension
28th Aug 20157:00 amRNSHalf Yearly Report
26th Aug 20152:22 pmRNSNotice of Results
24th Aug 20159:13 amRNSNotice of AGM
5th Aug 20153:45 pmRNSSecond Price Monitoring Extn
5th Aug 20153:40 pmRNSPrice Monitoring Extension
29th Jun 20153:40 pmRNSPrice Monitoring Extension
26th Jun 20153:45 pmRNSSecond Price Monitoring Extn
26th Jun 20153:40 pmRNSPrice Monitoring Extension
9th Jun 20153:40 pmRNSPrice Monitoring Extension
29th May 20157:00 amRNS1st Quarter Results
27th May 20152:28 pmRNSNotice of Results
13th May 20153:40 pmRNSPrice Monitoring Extension
12th May 20153:45 pmRNSSecond Price Monitoring Extn
12th May 20153:40 pmRNSPrice Monitoring Extension
7th May 20153:45 pmRNSSecond Price Monitoring Extn
7th May 20153:40 pmRNSPrice Monitoring Extension
5th May 20153:45 pmRNSSecond Price Monitoring Extn
5th May 20153:40 pmRNSPrice Monitoring Extension
1st May 20153:45 pmRNSSecond Price Monitoring Extn
1st May 20153:40 pmRNSPrice Monitoring Extension
30th Apr 201511:07 amRNSAnnual Financial Report
27th Apr 20153:45 pmRNSSecond Price Monitoring Extn
27th Apr 20153:40 pmRNSPrice Monitoring Extension
8th Apr 20153:40 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.